National Health Investors, Inc. (NHI) reported its Q3 2024 results, with a net income attributable to common stockholders of $0.65 per diluted share. The company is updating its 2024 annual guidance range. Fundamentals remain strong across much of the portfolio with occupancy and EBITDARM coverage improving sequentially from the second quarter across our major asset classes.
Net income attributable to common stockholders per diluted common share was $0.65.
NAREIT FFO per diluted common share was $1.03.
Normalized FFO per diluted common share was $1.03.
SHOP portfolio continues to improve with quarterly occupancy advancing 960 basis points year-over -year and 160 basis points sequentially to 88.6%.
NHI is updating its 2024 annual guidance range which includes the following: NAREIT FFO per diluted common share to a range of $4.39 - $4.41 from $4.50 - $4.54; Normalized FFO per diluted common share to a range of $4.43 - $4.44 from $4.52 - $4.56; and Normalized FAD to a range of $201.8 million - $202.5 million from $200.1 million - $201.8 million.